Heparin cofactor II in atherosclerotic lesions from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study

Abstract

Heparin cofactor II (HCII) is a serine protease inhibitor (serpin) that has been shown to be a predictor of decreased atherosclerosis in the elderly and protective against atherosclerosis in mice. HCII inhibits thrombin in vitro and HCII–thrombin complexes have been detected in human plasma. Moreover, the mechanism of protection against atherosclerosis in mice was determined to be the inhibition of thrombin. Despite this evidence, the presence of HCII in human atherosclerotic tissue has not been reported. In this study, using samples of coronary arteries obtained from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study, we explore the local relationship between HCII and (pro)thrombin in atherosclerosis. We found that HCII and (pro)thrombin are co-localized in the lipid-rich necrotic core of atheromas. A significant positive correlation between each protein and the severity of the atherosclerotic lesion was present. These results suggest that HCII is in a position to inhibit thrombin in atherosclerotic lesions where thrombin can exert a proatherogenic inflammatory response. However, these results should be tempered by the additional findings from this, and other studies, that indicate the presence of other plasma proteins (antithrombin, albumin, and α₁-protease inhibitor) in the same localized region of the atheroma.

Introduction

Heparin cofactor II (HCII) is a serine protease inhibitor (serpin) that has been strongly implicated in the inhibition of atherosclerosis (Aihara et al., 2007, Aihara et al., 2004, Huang et al., 2007, Tollefsen, 2007, Vicente et al., 2007). Individuals with high levels of HCII have been shown to have less atherosclerosis than their counterparts (Aihara et al., 2004), and HCII deficient mice show increased atherosclerotic plaque formation (Aihara et al., 2007, Vicente et al., 2007). Thrombin exhibits mitogenic and chemotactic activities that contribute to the chronic inflammatory processes of atherosclerosis (Baykal et al., 1995, Harker et al., 1995). Studies that examined restenosis after arterial stent placement showed that elevated blood concentrations of HCII were associated with decreased incidence of restenosis (Schillinger et al., 2004, Takamori et al., 2004); the processes that dominate restenosis, smooth muscle cell proliferation and migration, are also important processes in atherogenesis and can be induced by thrombin. HCII–thrombin complexes have been detected in human plasma (Liu et al., 1995) and, thrombin has been found in its active form in atherosclerotic lesions (Stoop et al., 2000). HCII inhibits thrombin at physiologically relevant rates only in the presence of glycosaminoglycans (GAGs) (Rau et al., 2007). Dermatan sulfate is the predominant antithrombotic GAG in the artery wall (Tovar et al., 2005). It specifically accelerates HCII inhibition of thrombin and has been shown to have decreased activity in atherosclerotic lesions as compared to normal tissue (Shirk et al., 2000). Although HCII is presumed to regulate thrombin in atherosclerosis, the presence of HCII in atherosclerotic lesions has not been reported.

In this study we utilized atherosclerotic lesions of coronary arteries sampled from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) research program. PDAY was established in 1985 to quantitatively assess the risk factors for coronary heart disease. Data and arterial samples from over 3000 individuals from the ages of 15–34 who died of external causes (accidents, homicides, suicides) were collected by fifteen cooperating centers across the United States and managed by the Department of Pathology at Louisiana State University Health Science Center. The data published using PDAY has greatly enhanced our understanding of atherosclerosis and its associated risk factors (see (McGill et al., 2008) for recent review).

We probed the atherosclerotic plaques for HCII, (pro)thrombin and several other proteins with the hypothesis that we would find decreased levels of HCII and increased levels of thrombin in more severe atherosclerotic plaques, reasoning that less HCII would result in decreased thrombin inhibition and therefore more severe atheromas.